AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 427007 — intervention group
Group type: COMPARATOR
Intervention: Control (nonfasted condition)
Number of subjects: 0
Study 31432744 — intervention group
Group type: EXPERIMENTAL
Intervention: Christianen et al. model for predicting physician-rated dysphagia
Number of subjects: 588
Study 28410791 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib 100 mg twice per day plus esomeprazole 20 mg once per day
Number of subjects: 514
Study 28410791 — intervention group
Group type: COMPARATOR
Intervention: Naproxen 500 mg twice per day plus esomeprazole 20 mg once per day
Number of subjects: 514
Study 26267726 — intervention group
Group type: EXPERIMENTAL
Intervention: Secukinumab 300 mg
Number of subjects: 367
Study 26267726 — intervention group
Group type: EXPERIMENTAL
Intervention: Secukinumab 150 mg
Number of subjects: 367
Study 23575220 — intervention group
Group type: EXPERIMENTAL
Intervention: Griseofulvin 15 mg/kg/day
Number of subjects: 113
Study 23575220 — intervention group
Group type: EXPERIMENTAL
Intervention: Griseofulvin 25 mg/kg/day
Number of subjects: 113
Study 23575220 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluconazole 4 mg/kg/day
Number of subjects: 113
Study 23575220 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluconazole 6 mg/kg/day
Number of subjects: 113
Study 21242997 — intervention group
Group type: EXPERIMENTAL
Intervention: Tilt angles of 10° increments (0° to 50°) in a manual wheelchair
Number of subjects: 18
Study 19106674 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic sigmoid resection (LSR)
Number of subjects: 104
Study 19106674 — intervention group
Group type: COMPARATOR
Intervention: Open sigmoid resection (OSR)
Number of subjects: 104
Study 17584749 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioural group treatment (CBT), n = 19
Number of subjects: 39
Study 17584749 — intervention group
Group type: COMPARATOR
Intervention: Waiting-list control, n = 20
Number of subjects: 39
Study 15177794 — intervention group
Group type: EXPERIMENTAL
Intervention: Phantom hand representing the unseen hand holding a tactile stimulus of same or different size
Number of subjects: 0
Study 15177794 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual reality box illusions
Number of subjects: 0
Study 12269650 — intervention group
Group type: EXPERIMENTAL
Intervention: Triamcinolone acetonide aqueous (TAA)
Number of subjects: 95
Study 9696254 — intervention group
Group type: EXPERIMENTAL
Intervention: Gingivitis scores
Number of subjects: 0
Study 9696254 — intervention group
Group type: COMPARATOR
Intervention: Plaque scores
Number of subjects: 0
Study 8606536 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended-release felodipine (10 mg once daily)
Number of subjects: 0
Study 8606536 — intervention group
Group type: COMPARATOR
Intervention: Slow-release nifedipine (20 mg twice daily)
Number of subjects: 0
Study 2672484 — intervention group
Group type: EXPERIMENTAL
Intervention: Lixiscope
Number of subjects: 24
Study 2672484 — intervention group
Group type: COMPARATOR
Intervention: Conventional X-ray
Number of subjects: 24
Study 361349 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucamethacin (420 mg/day)
Number of subjects: 100
Study 361349 — intervention group
Group type: COMPARATOR
Intervention: Indomethacin (100 mg/day)
Number of subjects: 100
Study 361349 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucamethacin (420 mg/day) in patients with gastro-duodenal pathology
Number of subjects: 100
Study 31444185 — intervention group
Group type: EXPERIMENTAL
Intervention: Online intervention to enhance problem solving ability
Number of subjects: 25
Study 31444185 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 25
Study 27884497 — intervention group
Group type: EXPERIMENTAL
Intervention: Rotator cuff muscle strengthening exercises
Number of subjects: 42
Study 27884497 — intervention group
Group type: COMPARATOR
Intervention: TENS and joint mobilization
Number of subjects: 42
Study 26498699 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone furoate nasal spray (FFNS)
Number of subjects: 40
Study 26498699 — intervention group
Group type: COMPARATOR
Intervention: Mometasone furoate nasal spray (MFNS)
Number of subjects: 40
Study 25079375 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical application of a mixture of two dimeticones of low viscosity (NYDA)
Number of subjects: 47
Study 25079375 — intervention group
Group type: COMPARATOR
Intervention: 0.05% solution of KMnO4
Number of subjects: 47
Study 23088223 — intervention group
Group type: EXPERIMENTAL
Intervention: FRAX® tool without bone mineral density (BMD)
Number of subjects: 770
Study 23088223 — intervention group
Group type: EXPERIMENTAL
Intervention: FRAX® tool with T-score of femoral neck (FN)
Number of subjects: 770
Study 23088223 — intervention group
Group type: EXPERIMENTAL
Intervention: FRAX® tool for hip fracture without BMD
Number of subjects: 770
Study 23088223 — intervention group
Group type: EXPERIMENTAL
Intervention: FRAX® tool for hip fracture with BMD
Number of subjects: 770
Study 23088223 — intervention group
Group type: EXPERIMENTAL
Intervention: Model with BMD alone
Number of subjects: 770
Study 23088223 — intervention group
Group type: EXPERIMENTAL
Intervention: Model with age alone
Number of subjects: 770
Study 23088223 — intervention group
Group type: EXPERIMENTAL
Intervention: ObsFx/ExpFx ratio for major fracture
Number of subjects: 770
Study 23088223 — intervention group
Group type: EXPERIMENTAL
Intervention: ObsFx/ExpFx ratio for hip fracture without BMD
Number of subjects: 770
Study 23088223 — intervention group
Group type: EXPERIMENTAL
Intervention: ObsFx/ExpFx ratio with BMD for major fracture
Number of subjects: 770
Study 23088223 — intervention group
Group type: EXPERIMENTAL
Intervention: ObsFx/ExpFx ratio with BMD for hip fracture
Number of subjects: 770
Study 19744889 — intervention group
Group type: EXPERIMENTAL
Intervention: Consultation training in patient‐centred counselling and cardiovascular prevention
Number of subjects: 19
Study 18036292 — intervention group
Group type: EXPERIMENTAL
Intervention: Shenfu injection (20 ml/L added to blood containing cardioplegic liquid)
Number of subjects: 40
Study 18036292 — intervention group
Group type: COMPARATOR
Intervention: Control group (4:1 blood containing cardioplegic liquid)
Number of subjects: 40
Study 14972481 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive biopsy group
Number of subjects: 9575
Study 14972481 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative biopsy group
Number of subjects: 9575
Study 14972481 — intervention group
Group type: EXPERIMENTAL
Intervention: No biopsy indication group
Number of subjects: 9575
Study 11564197 — intervention group
Group type: EXPERIMENTAL
Intervention: GP tutor visit
Number of subjects: 112
Study 11564197 — intervention group
Group type: EXPERIMENTAL
Intervention: Mailing
Number of subjects: 112
Study 11564197 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 112
Study 9627585 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl (3 micrograms/kg)
Number of subjects: 22
Study 9627585 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 8147361 — intervention group
Group type: EXPERIMENTAL
Intervention: famotidine 40 mg
Number of subjects: 594
Study 8147361 — intervention group
Group type: COMPARATOR
Intervention: ranitidine 300 mg
Number of subjects: 594
Study 3076792 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebuhaler (10 mg terbutaline sulphate four times daily)
Number of subjects: 13
Study 3076792 — intervention group
Group type: COMPARATOR
Intervention: Jet nebulizer (10 mg terbutaline sulphate four times daily)
Number of subjects: 13
Study 29515037 — intervention group
Group type: EXPERIMENTAL
Intervention: CYT107 (recombinant human IL-7)
Number of subjects: 27
Study 29515037 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 28835268 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative antibiotic prophylaxis (2000 mg of first-generation cephalosporin delivered intravenously)
Number of subjects: 454
Study 28835268 — intervention group
Group type: COMPARATOR
Intervention: No antibiotic prophylaxis
Number of subjects: 454
Study 26339178 — intervention group
Group type: EXPERIMENTAL
Intervention: Opposite Side (OS) position for changing compression
Number of subjects: 64
Study 26339178 — intervention group
Group type: COMPARATOR
Intervention: Same Side (SS) position for changing compression
Number of subjects: 64
Study 24035939 — intervention group
Group type: EXPERIMENTAL
Intervention: Garlic tablets at 300 mg
Number of subjects: 210
Study 24035939 — intervention group
Group type: EXPERIMENTAL
Intervention: Garlic tablets at 600 mg
Number of subjects: 210
Study 24035939 — intervention group
Group type: EXPERIMENTAL
Intervention: Garlic tablets at 900 mg
Number of subjects: 210
Study 24035939 — intervention group
Group type: EXPERIMENTAL
Intervention: Garlic tablets at 1200 mg
Number of subjects: 210
Study 24035939 — intervention group
Group type: EXPERIMENTAL
Intervention: Garlic tablets at 1500 mg
Number of subjects: 210
Study 24035939 — intervention group
Group type: COMPARATOR
Intervention: Atenolol (control)
Number of subjects: 210
Study 24035939 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 210
Study 21242022 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacological treatment with exercise programme
Number of subjects: 43
Study 21242022 — intervention group
Group type: COMPARATOR
Intervention: Pharmacological treatment only
Number of subjects: 43
Study 21242022 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 43
Study 18922829 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenalidomide and dexamethasone (LD)
Number of subjects: 0
Study 18922829 — intervention group
Group type: COMPARATOR
Intervention: Placebo and dexamethasone (PD)
Number of subjects: 0
Study 17029128 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyridoxine
Number of subjects: 24
Study 12711266 — intervention group
Group type: EXPERIMENTAL
Intervention: Group cognitive treatment for pathological gambling
Number of subjects: 58
Study 12711266 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 58
Study 16138577 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical treatment for patients with aberrant sperm nuclear proteins (n=30)
Number of subjects: 199
Study 10077290 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual-assisted cognitive-behaviour therapy (MACT)
Number of subjects: 34
Study 10077290 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 34
Study 7740627 — intervention group
Group type: EXPERIMENTAL
Intervention: REC diet (low-fat, 28% of energy, high-fibre, 3.3 g/MJ)
Number of subjects: 21
Study 2258871 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketanserin 40 mg twice daily
Number of subjects: 31
Study 2258871 — intervention group
Group type: COMPARATOR
Intervention: Metoprolol 100 mg twice daily
Number of subjects: 31
Study 7010882 — intervention group
Group type: EXPERIMENTAL
Intervention: Gentamicin sulfate ophthalmic solution
Number of subjects: 60
Study 7010882 — intervention group
Group type: COMPARATOR
Intervention: Chloramphenicol solution
Number of subjects: 60
Study 7010882 — intervention group
Group type: COMPARATOR
Intervention: Oxytetracycline‐polymyxin B ointment
Number of subjects: 60
Study 7010882 — intervention group
Group type: COMPARATOR
Intervention: Sulphamethizole
Number of subjects: 60
Study 7010882 — intervention group
Group type: COMPARATOR
Intervention: Bacitracin‐neomycin
Number of subjects: 60
Study 7010882 — intervention group
Group type: COMPARATOR
Intervention: Ristocetin‐polymyxin B solutions
Number of subjects: 60
Study 30528516 — intervention group
Group type: EXPERIMENTAL
Intervention: Femtosecond laser-assisted cataract surgery
Number of subjects: 70
Study 30528516 — intervention group
Group type: EXPERIMENTAL
Intervention: Femtosecond laser-assisted cataract surgery with preoperative NSAID
Number of subjects: 70
Study 30528516 — intervention group
Group type: COMPARATOR
Intervention: Conventional phacoemulsification
Number of subjects: 70
Study 27696593 — intervention group
Group type: EXPERIMENTAL
Intervention: Inappropriate therapies (IT) in men
Number of subjects: 2510
Study 27696593 — intervention group
Group type: EXPERIMENTAL
Intervention: Inappropriate therapies (IT) in women
Number of subjects: 2510
Study 27696593 — intervention group
Group type: EXPERIMENTAL
Intervention: Inappropriate shock therapy
Number of subjects: 2510
Study 27696593 — intervention group
Group type: EXPERIMENTAL
Intervention: Appropriate shock therapy
Number of subjects: 2510
Study 26072346 — intervention group
Group type: EXPERIMENTAL
Intervention: Patching (3 hours daily for 5 months, followed by 1 month of no patching)
Number of subjects: 201
Study 26072346 — intervention group
Group type: COMPARATOR
Intervention: Observation (no treatment for 6 months)
Number of subjects: 201
Study 26072346 — intervention group
Group type: EXPERIMENTAL
Intervention: Patching
Number of subjects: 201
Study 26072346 — intervention group
Group type: COMPARATOR
Intervention: Observation
Number of subjects: 201
Study 23826685 — intervention group
Group type: EXPERIMENTAL
Intervention: Health status guided treatment algorithm based on the Clinical COPD Questionnaire (CCQ)
Number of subjects: 330
Study 23826685 — intervention group
Group type: COMPARATOR
Intervention: Usual care based on lung function
Number of subjects: 330
Study 21868687 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance Training (RT)
Number of subjects: 12
Study 21868687 — intervention group
Group type: EXPERIMENTAL
Intervention: Plyometrics (PLY)
Number of subjects: 12
Study 21868687 — intervention group
Group type: COMPARATOR
Intervention: Control (no-exercise)
Number of subjects: 12
Study 19695072 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma expander (hydroxyethyl starch) during surgery
Number of subjects: 74
Study 19695072 — intervention group
Group type: COMPARATOR
Intervention: No plasma expander during surgery
Number of subjects: 74
Study 17908522 — intervention group
Group type: EXPERIMENTAL
Intervention: Staphylococcus aureus bacteremia (SAB)
Number of subjects: 198
Study 17908522 — intervention group
Group type: COMPARATOR
Intervention: Staphylococcus aureus infective endocarditis (SAIE)
Number of subjects: 198
Study 17908522 — intervention group
Group type: EXPERIMENTAL
Intervention: Methicillin-resistant Staphylococcus aureus (MRSA) in patients with SAB
Number of subjects: 198
Study 15281513 — intervention group
Group type: EXPERIMENTAL
Intervention: IV morphine (0.125 mg/kg)
Number of subjects: 10
Study 15281513 — intervention group
Group type: EXPERIMENTAL
Intervention: codeine (1 mg/kg)
Number of subjects: 10
Study 15281513 — intervention group
Group type: EXPERIMENTAL
Intervention: tramadol (1.25 mg/kg)
Number of subjects: 10
Study 15281513 — intervention group
Group type: COMPARATOR
Intervention: placebo (10 mL 0.9% w/v sodium chloride)
Number of subjects: 10
Study 11199953 — intervention group
Group type: EXPERIMENTAL
Intervention: amisulpride 400 mg/day (N = 12)
Number of subjects: 51
Study 11199953 — intervention group
Group type: EXPERIMENTAL
Intervention: olanzapine 20 mg/day (N = 13)
Number of subjects: 51
Study 11199953 — intervention group
Group type: EXPERIMENTAL
Intervention: sertindole 12 mg/day (N = 13)
Number of subjects: 51
Study 11199953 — intervention group
Group type: EXPERIMENTAL
Intervention: clozapine 100 mg/day (N = 13)
Number of subjects: 51
Study 11199953 — intervention group
Group type: COMPARATOR
Intervention: healthy controls (N = 70)
Number of subjects: 51
Study 9449585 — intervention group
Group type: EXPERIMENTAL
Intervention: Betanecholchloride (50 mg three times a day from the 3rd postoperative day)
Number of subjects: 40
Study 9449585 — intervention group
Group type: COMPARATOR
Intervention: Control group (received betanecholchloride only if residual urine persisted above 50 ml after the 10th postoperative day)
Number of subjects: 40
Study 9508956 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile Dental System (MDS)
Number of subjects: 0
Study 9508956 — intervention group
Group type: EXPERIMENTAL
Intervention: MDS personnel
Number of subjects: 0
Study 31776561 — intervention group
Group type: EXPERIMENTAL
Intervention: GHB detection in postmortem heart blood samples
Number of subjects: 348
Study 31776561 — intervention group
Group type: EXPERIMENTAL
Intervention: Secondary matrices analysis (peripheral blood, urine, vitreous humor, liver homogenate, brain homogenate)
Number of subjects: 348
Study 29679748 — intervention group
Group type: EXPERIMENTAL
Intervention: On-site meetings
Number of subjects: 39
Study 29679748 — intervention group
Group type: COMPARATOR
Intervention: Remote meetings
Number of subjects: 39
Study 26715658 — intervention group
Group type: EXPERIMENTAL
Intervention: Inside brachial plexus sheath injection
Number of subjects: 60
Study 26715658 — intervention group
Group type: COMPARATOR
Intervention: Outside brachial plexus sheath injection
Number of subjects: 60
Study 26420240 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional physical therapy with low-level laser therapy (protocol B)
Number of subjects: 100
Study 26420240 — intervention group
Group type: COMPARATOR
Intervention: Conventional physical therapy (protocol A)
Number of subjects: 100
Study 23103498 — intervention group
Group type: EXPERIMENTAL
Intervention: BQ-123 (endothelin type A receptor antagonist)
Number of subjects: 15
Study 23103498 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 21968662 — intervention group
Group type: EXPERIMENTAL
Intervention: Tazarotene gel (0.1%) pretreatment for one week before ALA PDT
Number of subjects: 10
Study 21968662 — intervention group
Group type: COMPARATOR
Intervention: Control (no pretreatment)
Number of subjects: 10
Study 21968662 — intervention group
Group type: EXPERIMENTAL
Intervention: Tazarotene gel (0.1%) pretreatment
Number of subjects: 10
Study 18211363 — intervention group
Group type: EXPERIMENTAL
Intervention: Complementary foods fortified with reduced iron
Number of subjects: 0
Study 18211363 — intervention group
Group type: EXPERIMENTAL
Intervention: Complementary foods fortified with ferrous fumarate
Number of subjects: 0
Study 18211363 — intervention group
Group type: EXPERIMENTAL
Intervention: Complementary foods fortified with reduced iron (vanilla-flavored)
Number of subjects: 0
Study 18211363 — intervention group
Group type: EXPERIMENTAL
Intervention: Complementary foods fortified with ferrous fumarate (vanilla-flavored)
Number of subjects: 0
Study 18211363 — intervention group
Group type: EXPERIMENTAL
Intervention: Sources of iron for women (reduced iron)
Number of subjects: 0
Study 18211363 — intervention group
Group type: EXPERIMENTAL
Intervention: Sources of iron for women (ferrous fumarate)
Number of subjects: 0
Study 16492208 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C (1 g) therapy for 2 days prior to re-testing
Number of subjects: 20
Study 16492208 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 20
Study 12750211 — intervention group
Group type: EXPERIMENTAL
Intervention: New pacing technologies for heart failure; specific details on dosage and duration not available.
Number of subjects: 0
Study 12750211 — intervention group
Group type: COMPARATOR
Intervention: Pharmacological treatment; specific details on dosage and duration not available.
Number of subjects: 0
Study 10916529 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled beclomethasone, mean daily dose of 2861 micrograms/day, decreasing during treatment.
Number of subjects: 24
Study 10916529 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term oral prednisone, mean yearly dose of 371 mg/year, decreasing during treatment.
Number of subjects: 24
Study 8631014 — intervention group
Group type: EXPERIMENTAL
Intervention: High levels of alkyltransferase
Number of subjects: 167
Study 8631014 — intervention group
Group type: COMPARATOR
Intervention: Low levels of alkyltransferase
Number of subjects: 167
Study 8631014 — intervention group
Group type: EXPERIMENTAL
Intervention: All tumors
Number of subjects: 167
Study 8631014 — intervention group
Group type: EXPERIMENTAL
Intervention: Glioblastoma multiforme
Number of subjects: 167
Study 1385069 — intervention group
Group type: EXPERIMENTAL
Intervention: Somatostatin
Number of subjects: 0
Study 1385069 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide (long-acting analogue of somatostatin)
Number of subjects: 0
Study 4068043 — intervention group
Group type: EXPERIMENTAL
Intervention: 11-hour EMS program
Number of subjects: 34
Study 4068043 — intervention group
Group type: COMPARATOR
Intervention: No-treatment control condition
Number of subjects: 34
Study 30408106 — intervention group
Group type: EXPERIMENTAL
Intervention: Regorafenib
Number of subjects: 0
Study 30408106 — intervention group
Group type: COMPARATOR
Intervention: Best supportive care (placebo)
Number of subjects: 0
Study 28102167 — intervention group
Group type: EXPERIMENTAL
Intervention: Sanatorium-based rehabilitation
Number of subjects: 80
Study 28102167 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional rehabilitation supplemented with natural methods at a sanatorium
Number of subjects: 80
Study 28102167 — intervention group
Group type: COMPARATOR
Intervention: Outpatient rehabilitation
Number of subjects: 80
Study 23994055 — intervention group
Group type: EXPERIMENTAL
Intervention: Arthrocentesis as initial treatment (n = 40)
Number of subjects: 80
Study 23994055 — intervention group
Group type: COMPARATOR
Intervention: Conservative treatment including soft diet, physical treatment, and occlusal splint therapy (n = 40)
Number of subjects: 80
Study 23265033 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol (2.5 mg/kg)
Number of subjects: 82
Study 23265033 — intervention group
Group type: COMPARATOR
Intervention: Thiopental (5 mg/kg)
Number of subjects: 82
Study 20619238 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose bolus tirofiban administered prehospital
Number of subjects: 320
Study 20619238 — intervention group
Group type: COMPARATOR
Intervention: High-dose bolus tirofiban administered in the catheterization laboratory
Number of subjects: 320
Study 17916138 — intervention group
Group type: EXPERIMENTAL
Intervention: Azimilide 125 mg daily
Number of subjects: 482
Study 17916138 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 482
Study 16105524 — intervention group
Group type: EXPERIMENTAL
Intervention: Excision and primary closure
Number of subjects: 100
Study 16105524 — intervention group
Group type: COMPARATOR
Intervention: Rhomboid excision and Limberg flap
Number of subjects: 100
Study 11800502 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorazepam 0.026 mg/kg
Number of subjects: 12
Study 11800502 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorazepam 0.038 mg/kg
Number of subjects: 12
Study 11800502 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 10411788 — intervention group
Group type: EXPERIMENTAL
Intervention: Gonadotropin-releasing hormone agonist
Number of subjects: 24
Study 10411788 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24